Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma: Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM, Institut Gustave Roussy, Villejuif, France

✍ Scribed by Donald L. Trump

• Book ID: 116956601
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 76 KB
• Volume: 27
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2009.07.007